Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

SynAct Pharma

14.32 SEK+8.32 %16/11 17:29
Less than 1K followers

SYNACT

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+8.32 %
-15.76 %
-28.18 %
-1.10 %
-36.64 %
-32.61 %
+105.85 %
-88.37 %
+210.66 %

SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.

Read more
Market cap
804.98M SEK
Turnover
3.24M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Financial calendar
18/2
2027

Annual report '26

Press release2026-11-16 16:25

SynAct Pharma CEO has acquired shares in the company

SynAct Pharma
Press release2026-11-16 16:25

SynAct Pharmas VD har förvärvat aktier i bolaget

SynAct Pharma
Press release2026-11-16 07:00

Sten Sörensen avgår från SynAct Pharmas styrelse

SynAct Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-11-16 07:00

Sten Sörensen resign from Board of Directors of SynAct Pharma

SynAct Pharma
Regulatory press release2026-11-13 08:00

SynAct Pharma meddelar Notice of Allowance för ett amerikanskt patent som omfattar resomelagon-tabletten

SynAct Pharma
Regulatory press release2026-11-13 08:00

SynAct Pharma announces Notice of Allowance of a US patent covering the resomelagon tablet

SynAct Pharma
Press release2026-11-04 15:00

SynAct Pharma meddelar att bolaget kommer att delta och presentera vid kommande investerarkonferenser

SynAct Pharma
Press release2026-11-04 15:00

SynAct Pharma announces attendance and presentation at upcoming investor conferences

SynAct Pharma
Press release2026-11-03 15:44

BioStock: BioVal™-analys av SynActs resomelagon – tre indikationer med ett kombinerat värde om 2,9 miljarder kronor

SynAct Pharma
Press release2026-11-03 15:44

BioStock: BioVal™ analysis of SynAct’s resomelagon – three indications with a combined value of SEK 2.9B

SynAct Pharma
Press release2026-11-03 15:36

SynAct Pharma meddelar att BioVal BioStock Analytics inleder analysbevakning av bolaget

SynAct Pharma
Press release2026-11-03 15:36

SynAct Pharma announces initiation of coverage by BioVal BioStock Analytics

SynAct Pharma
Press release2026-11-03 14:02

BioStock: SynAct sharpens its phase III plans for resomelagon

SynAct Pharma
Regulatory press release2026-11-03 07:30

SynAct Pharma publicerar delårsrapport för tredje kvartalet 2026

SynAct Pharma
Regulatory press release2026-11-03 07:30

SynAct Pharma publishes Q3 2026 interim results

SynAct Pharma
Press release2026-10-28 10:44

BioStock: SynAct on signing resomelagon’s first commercial partner

SynAct Pharma
Press release2026-10-27 14:55

SynAct Pharma ingår det första kommersiella partnerskapsavtalet för resomelagon med ledande brasilianskt läkemedelsbolag

SynAct Pharma
Press release2026-10-27 14:55

SynAct Pharma signs first commercial partnership for resomelagon with leading Brazilian pharmaceutical company

SynAct Pharma
Press release2026-09-24 12:18

BioStock: Video from SynAct Pharma's presentation at BioStock Investing in Life Science 2026

SynAct Pharma
Press release2026-09-24 10:56

BioStock: Video from SynAct Pharma's presentation at BioStock Investing in Life Science 2026

SynAct Pharma